Literature DB >> 33603072

Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin.

Bo Ryoung Park1, Ki-Hye Kim1, Tatiana Kotomina2, Min-Chul Kim1,3, Young-Man Kwon1, Subbiah Jeeva1, Yu-Jin Jung1, Noopur Bhatnagar1, Irina Isakova-Sivak2, Daria Mezhenskaya2, Larisa Rudenko2, Bao-Zhong Wang1, Sang-Moo Kang4.   

Abstract

Hemagglutinin (HA)-based current vaccines provide suboptimum cross protection. Influenza A virus contains an ion channel protein M2 conserved extracellular domain (M2e), a target for developing universal vaccines. Here we generated reassortant influenza virus rgH3N2 4xM2e virus (HA and NA from A/Switzerland/9715293/2013/(H3N2)) expressing chimeric 4xM2e-HA fusion proteins with 4xM2e epitopes inserted into the H3 HA N-terminus. Recombinant rgH3N2 4xM2e virus was found to retain equivalent growth kinetics as rgH3N2 in egg substrates. Intranasal single inoculation of mice with live rgH3N2 4xM2e virus was effective in priming the induction of M2e specific IgG antibody responses in mucosal and systemic sites as well as T cell responses. The rgH3N2 4xM2e primed mice were protected against a broad range of different influenza A virus subtypes including H1N1, H3N2, H5N1, H7N9, and H9N2. The findings support a new approach to improve the efficacy of current vaccine platforms by recombinant influenza virus inducing immunity to HA and cross protective M2e antigens.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33603072      PMCID: PMC7893060          DOI: 10.1038/s41598-021-83704-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  49 in total

1.  Universal influenza A vaccine: optimization of M2-based constructs.

Authors:  Marina De Filette; Willy Min Jou; Ashley Birkett; Katie Lyons; Brian Schultz; Anne Tonkyro; Stephanie Resch; Walter Fiers
Journal:  Virology       Date:  2005-06-20       Impact factor: 3.616

2.  Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans.

Authors:  Weimin Zhong; Carrie Reed; Patrick J Blair; Jacqueline M Katz; Kathy Hancock
Journal:  J Infect Dis       Date:  2013-12-10       Impact factor: 5.226

3.  Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.

Authors:  Min-Chul Kim; Yu-Na Lee; Eun-Ju Ko; Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Jae-Min Song; Byung-Min Song; Youn-Jeong Lee; Jun-Gu Choi; Hyun-Mi Kang; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2014-03-04       Impact factor: 11.454

4.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

5.  A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.

Authors:  Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Andrew T Gewirtz; Sang-Moo Kang
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

6.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

7.  Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions.

Authors:  S L Zebedee; R A Lamb
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

8.  Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine.

Authors:  Eunha Shim; Shawn T Brown; Jay DePasse; Mary Patricia Nowalk; Jonathan M Raviotta; Kenneth J Smith; Richard K Zimmerman
Journal:  Am J Prev Med       Date:  2016-04-11       Impact factor: 5.043

9.  Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.

Authors:  Hamidreza Hashemi; Somayeh Pouyanfard; Mojgan Bandehpour; Zahra Noroozbabaei; Bahram Kazemi; Xavier Saelens; Talat Mokhtari-Azad
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

10.  Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2.

Authors:  JingQi Feng; Manxin Zhang; Krystyna Mozdzanowska; Darya Zharikova; Henry Hoff; William Wunner; Robert B Couch; Walter Gerhard
Journal:  Virol J       Date:  2006-12-06       Impact factor: 4.099

View more
  8 in total

1.  Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.

Authors:  Bo Ryoung Park; Jeeva Subbiah; Ki-Hye Kim; Young-Man Kwon; Judy Oh; Min-Chul Kim; Chong-Hyun Shin; Baik Lin Seong; Sang-Moo Kang
Journal:  Virology       Date:  2021-12-10       Impact factor: 3.616

2.  Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants.

Authors:  Yura Shin; Jeonghun Kim; Jong Hyeon Seok; Heedo Park; Hye-Ran Cha; Si Hwan Ko; Jae Myun Lee; Man-Seong Park; Jung-Hwan Park
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

3.  Thermostable H1 hemagglutinin stem with M2e epitopes provides broad cross-protection against group1 and 2 influenza A viruses.

Authors:  Jeeva Subbbiah; Judy Oh; Ki-Hye Kim; Chong Hyun Shin; Bo Ryoung Park; Noopur Bhatnagar; Yu-Jin Jung; Youri Lee; Bao-Zhong Wang; Baik-Lin Seong; Sang-Moo Kang
Journal:  Mol Ther Methods Clin Dev       Date:  2022-05-29       Impact factor: 5.849

4.  A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine.

Authors:  Jeeva Subbiah; Judy Oh; Ki-Hye Kim; Chong-Hyun Shin; Bo Ryoung Park; Noopur Bhatnagar; Baik-Lin Seong; Bao-Zhong Wang; Sang-Moo Kang
Journal:  NPJ Vaccines       Date:  2022-06-29       Impact factor: 9.399

Review 5.  Progress towards the Development of a Universal Influenza Vaccine.

Authors:  Wen-Chien Wang; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Viruses       Date:  2022-07-30       Impact factor: 5.818

6.  Enhancing neutralizing activity against influenza H1N1/PR8 by engineering a single-domain VL-M2 specific into a bivalent form.

Authors:  Phuong Thi Hoang; Quynh Xuan Thi Luong; Seungchan Cho; Yongjun Lee; Kyungho Na; Ramadhani Qurrota Ayun; Thuy Thi Bich Vo; Taehyun Kim; Sukchan Lee
Journal:  PLoS One       Date:  2022-08-31       Impact factor: 3.752

Review 7.  Targeting Antigens for Universal Influenza Vaccine Development.

Authors:  Quyen-Thi Nguyen; Young-Ki Choi
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

8.  Universal Live-Attenuated Influenza Vaccine Candidates Expressing Multiple M2e Epitopes Protect Ferrets against a High-Dose Heterologous Virus Challenge.

Authors:  Daria Mezhenskaya; Irina Isakova-Sivak; Victoria Matyushenko; Svetlana Donina; Andrey Rekstin; Konstantin Sivak; Kirill Yakovlev; Anastasia Katelnikova; Kirill Kryshen; Valery Makarov; Larisa Rudenko
Journal:  Viruses       Date:  2021-06-30       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.